艾尔齐医药公司将于10月23日举办一个在线活动, 罗尔夫·卡尔斯博士将与其讨论ACD440 - - 一种治疗慢性疼痛的非阿片类止痛药, 处于第二阶段试验中. AlzeCure Pharma hosts an online event on 23rd October featuring Dr. Rolf Karlsten to discuss ACD440, a non-opioid analgesic for chronic pain, in Phase II trials.
AlzeCure Pharma将于10月23日主办一场现场活动, 由Rolf Karlsten博士主讲, 讨论ACD440, AlzeCure Pharma will host a live event on October 23, featuring Dr. Rolf Karlsten, to discuss ACD440, a novel non-opioid analgesic in phase II trials for chronic neuropathic pain. 这种局部凝是一种TRPV1抗剂,在试验中显示疼痛减少了50%. This topical gel, a TRPV1 antagonist, demonstrated a 50% reduction in pain during trials. 会议将讨论疼痛管理方面的进展, 并包括有关AlzeCure正在开发用于治疗各种神经疾病的药物的问答. The session will cover pain management advancements and include a Q&A about AlzeCure's ongoing drug development for various neurological conditions. 活动将在线提供。 The event will be accessible online.